New drug combo aims to tackle tough lymphoma
NCT ID NCT07197307
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 24 times
Summary
This study tests a combination of two drugs, loncastuximab tesirine and epcoritamab, in people with aggressive B-cell lymphoma that has come back or not responded to treatment. The goal is to see if the combination can shrink or eliminate the cancer. About 120 adults who have already tried at least one prior therapy, including possibly CAR-T cells, will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitätsklinikum Münster, Medizinische Klinik A
Münster, 48149, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.